LEO Pharma signed a definitive agreement to acquire Replay for $50M upfront plus undisclosed milestones and tiered single-digit royalties, adding a preclinical HSV gene therapy platform targeting dystrophic epidermolysis bullosa to LEO's rare dermatology pipeline.
Key facts
AnnouncedApr 30, 2026
Deal value$50M
Deal typeAcquisition/Merger
Therapeutic areaDystrophic epidermolysis bullosa (DEB) and other rare genetic dermatological conditions
IndicationsDystrophic epidermolysis bullosa (DEB) and other rare genetic dermatological conditions
Key assetsPreclinical HSV-vector gene therapy (topical gel) for DEB
MechanismHigh-payload herpes simplex virus delivery vector formulated as a topical gel to deliver therapeutic genes to skin cells